Skip to main content

Clinical Trials

NCT05429541 - Pneumococcal Carriage and Serotype Distribution in Children With Otitis Media in Malaysia.

Pneumococcal Carriage and Serotype Distribution in Children With Otitis Media in Malaysia.
Conditions:   Streptococcus Pneumonia;   Otitis Media
Intervention:  
Sponsors:   International Medical University;   International Islamic University Malaysia;   Universiti Putra Malaysia;   University of Southampton;   Merck Sharp & Dohme LLC;   Hospital Serdang
Recruiting
Pub Date: 
Thursday, June 23, 2022 - 9:00am
Study URL: 
http://classic.clinicaltrials.gov/ct2/show/NCT05429541?term=genomics%20DNA&%3Brecrs=abc

NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Regorafenib
Sponsors:   Gerald Batist;   Bayer;   Quebec Clinical Research Organization in Cancer
Recruiting
Pub Date: 
Tuesday, September 24, 2013 - 9:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT01949194?term=genomics%20DNA&%3Brecrs=abc

NCT02984059 - Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease

Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease
Condition:   Inflammatory Bowel Disease
Interventions:   Genetic: Genomic DNA;   Genetic: RNA analysis;   Genetic: Microbiome;   Other: Calprotectin;   Other: Pain questionnaires;   Other: Anxiety/Depression Questionnaires
Sponsor:   Connecticut Children's Medical Center
Recruiting
Pub Date: 
Tuesday, December 6, 2016 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT02984059?term=genomics%20DNA&%3Brecrs=abc

NCT02980536 - cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China

cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Conditions:   Nonsmall Cell Lung Cancer;   Adenocarcinoma
Intervention:  
Sponsors:   Berry Genomics Co., Ltd.;   Shanghai Chest Hospital;   Baotou Cancer Hospital Inner-Mongolia
Recruiting
Pub Date: 
Friday, December 2, 2016 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT02980536?term=genomics%20DNA&%3Brecrs=abc

NCT03519503 - Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety

Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety
Condition:   Growth and Development
Intervention:  
Sponsor:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting
Pub Date: 
Wednesday, May 9, 2018 - 9:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03519503?term=genomics%20DNA&%3Brecrs=abc

NCT03832569 - Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Conditions:   Solid Tumors;   Identified by NGS, PCR or IHC
Interventions:   Drug: Pembrolizumab;   Drug: Placebo
Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
Recruiting
Pub Date: 
Wednesday, February 6, 2019 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03832569?term=genomics%20DNA&%3Brecrs=abc

NCT03926338 - Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colon Cancer

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colon Cancer
Conditions:   Colon Cancer;   MSI-H
Interventions:   Drug: Neoadjuvant therapy with PD-1 inhibitor plus COX inhibitor;   Drug: Neoadjuvant therapy with PD-1 inhibitor
Sponsor:   Sun Yat-sen University
Recruiting
Pub Date: 
Wednesday, April 24, 2019 - 9:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03926338?term=genomics%20DNA&%3Brecrs=abc

NCT03832569 - Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Conditions:   Solid Tumors;   Identified by NGS, PCR or IHC
Interventions:   Drug: Pembrolizumab;   Drug: Placebo
Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
Recruiting
Pub Date: 
Wednesday, February 6, 2019 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03832569?term=genomics%20DNA&%3Brecrs=abc

NCT03880019 - Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma

Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma
Conditions:   Stage III Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IV Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Interventions:   Drug: Olaparib;   Drug: Temozolomide
Sponsor:   National Cancer Institute (NCI)
Recruiting
Pub Date: 
Tuesday, March 19, 2019 - 9:00am
Study URL: 
http://clinicaltrials.gov/ct2/show/NCT03880019?term=genomics%20DNA&%3Brecrs=abc

NCT03816917 - Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral
Conditions:   Psoriasis;   Psoriatic Arthritis;   Psoriasis Vulgaris;   Psoriatic Nail
Interventions:   Other: cutaneous parameters of psoriasis (exposure);   Other: comorbidity (exposure);   Other: family history (exposure);   Other: lifestyle (exposure);   Other: patient reported outcomes (exposure);   Other: inflammatory markers (exposure);   Other: genetic (exposure)
Sponsors:   Radboud University;   Sint Maartenskliniek
Not yet recruiting
Pub Date: 
Friday, January 25, 2019 - 10:00am
Study URL: 
http://clinicaltrials.gov/ct2/show/NCT03816917?term=genomics%20DNA&%3Brecrs=abc

NCT03386929 - Survival Prolongation by Rationale Innovative Genomics

Survival Prolongation by Rationale Innovative Genomics
Conditions:   Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Stage III
Interventions:   Drug: Avelumab;   Drug: Axitinib;   Drug: Palbociclib
Sponsors:   Worldwide Innovative Networking Association;   ARC Foundation for Cancer Research;   Pfizer
Recruiting
Pub Date: 
Friday, December 29, 2017 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03386929?term=genomics%20DNA&%3Brecrs=abc

NCT02345356 - A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
Conditions:   Atrial Fibrillation;   Deep Vein Thrombosis;   Cardiac Valvular Insufficiency;   Coagulopathies;   Pulmonary Embolism
Interventions:   Genetic: Genotype-guided;   Other: Standard-of-Care
Sponsors:   University of Puerto Rico;   National Institute on Minority Health and Health Disparities (NIMHD);   Genomas, Inc
Recruiting
Pub Date: 
Monday, January 26, 2015 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT02345356?term=genomics%20DNA&%3Brecrs=abc

NCT03386929 - Survival Prolongation by Rationale Innovative Genomics

Survival Prolongation by Rationale Innovative Genomics
Conditions:   Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Stage III
Interventions:   Drug: Avelumab;   Drug: Axitinib;   Drug: Palbociclib
Sponsors:   Worldwide Innovative Networking Association;   ARC Foundation for Cancer Research;   Pfizer
Recruiting
Pub Date: 
Friday, December 29, 2017 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03386929?term=genomics%20DNA&%3Brecrs=abc